Wave Life Sciences begins Phase Ib/IIa trials of two Huntington ’s disease drugs

Wave Life Sciences has begun new Phase Ib/IIa clinical trials (PRECISION-HD1 and PRECISION-HD2) of WVE-120101 and WVE-120102 to treat patients suffering with Huntington ’s disease (HD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news